Is disease flare a problem?
Is disease flare a problem?
复制标题
疾病爆发是一个问题吗？
作者：
C. Mahler
当首次给予先前未经治疗的晚期前列腺癌患者时，黄体生成素释放激素（LHRH）类似物会引起垂体黄体生成素水平短暂升高。 LH 增加的结果是，在最初的 2 至 3 天内，睾酮水平会激增，这可能会导致症状恶化。关于这种耀斑的首次报告都是轶事，在大多数研究中，据报道，耀斑的发生率为 4‐33%。这种差异主要是由于对耀斑现象的定义的混淆造成的。临床耀斑（其表现为癌症相关症状的主观或客观恶化）和生化耀斑（LHRH类似物给药导致的，发生在大多数患者中，其特征是睾酮、前列腺酸性磷酸酶和前列腺特异性抗原增加）之间没有区别。
When given for the first time to previously untreated patients with advanced prostate cancer, luteinizing hormone‐releasing hormone (LHRH) analogs induce a transient rise in pituitary luteinizing hormone levels. As a consequence of this increase of LH, there is, within the first 2 to 3 days, a surge of testosterone, which can cause an exacerbation of the symptoms. First reports concerning this flare have been anecdotal, and in most studies, flare is reported with an incidence of 4‐33%. This variance is due mainly to the confusion about the definition of the flare phenomenon. No distinctions have been made between clinical flare, with its manifestations of subjective or objective aggravation of cancer related symptoms, and the biochemical flare that results of the LHRH analog administration and that occurs in a majority of patients and is characterized by increases in testosterone, prostatic acid phosphatase, and prostate specific antigen.